Precision BioSciences Inc (DTIL)

[MI Dendream]

Just taking a quick look at where things were.

Avexis was a vector gene therapy company using AAV9 with 15 successfully treated human SMA babies, a few very early other MD vectors, and some preliminary CAR-T work. An inferior technology IMO with some questions of durability and long term safety. Novartis snatched them up for $8.7B.

https://www.fiercebiotech.com/biotech/novartis-inks-8-7b-avexis-buyout-to-build-gene-therapy-unit

Spark was a gene therapy company with a host of genetic eye disease vector gene therapies on market and in development with very limited revenuee from these conditions. Roche bought them for $4.3B.

https://www.fiercepharma.com/pharma/roche-to-wrap-up-4-3b-spark-deal-after-antitrust-ordeal-ends-ftc-thumbs-up

Astellas with early vector company Audentes $3B. https://www.fiercebiotech.com/biotech/astellas-inks-3b-audentes-buyout-to-expand-gene-therapy

All inferior technology for many reasons…Eli Lilly already thinks our first six genes are worth $2.6B plus royalties on sales. What is the whole platform and CAR-T program worth?